KRAS and cancer: In addition to overcoming resistance to BRAF inhibitors in melanoma cells and EGFR-tyrosine kinase inhibitor resistance in non–small lung cancer cells, HA15 lowered viability of a wide range of cancer cells, including those bearing various KRAS mutations (51, 100, 101).